Eucrates Biomedical Acquisition Corp.
EUCR · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|
| Valuation | |||
| PEG Ratio | 0.12 | 0.00 | 0.00 |
| FCF Yield | -2.12% | -1.73% | 0.00% |
| EV / EBITDA | -11.57 | -5.50 | 15,675.20 |
| Quality | |||
| ROIC | -12.88% | -0.71% | 0.01% |
| Gross Margin | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -0.26 | -0.13 | – |
| Growth | |||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% |
| Free Cash Flow Growth | -25.53% | 0.00% | 0.00% |
| Safety | |||
| Net Debt / EBITDA | -0.02 | 0.01 | -64.15 |
| Interest Coverage | 0.00 | 0.00 | 0.00 |
| Efficiency | |||
| Inventory Turnover | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 |